Optimi Health lines up larger psilocybin trial and MDMA pivotal study for 2027
The Canadian psychedelics developer wants to turn an open-label depression study into a blinded 200-patient trial, and says its PTSD Phase 3 already has regulatory clearance.
18 Nov 2026 · Optimi Health Corp. OPTH · Company news
Optimi Health Corp. is trying to move both of its lead psychedelic programmes into more rigorous clinical territory, a step that matters for any company hoping to turn early-stage promise into an asset that partners or investors can value. The Canadian developer set out its plans on 18 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Optimi Health Corp. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More Pipeline & R&DAll →
Pipeline & R&D
Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC
18 Nov 2026 · Summit Therapeutics Inc. SMMT · Company news
Pipeline & R&D
NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma
18 Nov 2026 · Neonc Technologies Holdings, Inc. NTHI · Company news
Pipeline & R&D
Can-Fite completes dosing in interim cohort of Phase III piclidenoson psoriasis trial
18 Nov 2026 · Can-Fite BioPharma Ltd. CANF · Company news
Pipeline & R&D
Inhibrx reports 62.7% response rate for ozekibart combination in relapsed Ewing sarcoma
17 Nov 2026 · Inhibrx Biosciences, Inc. INBX · Company news
Pipeline & R&D
Adagene and City of Hope launch Phase 1 trial of ivonescimab plus muzastotug in colorectal cancer
17 Nov 2026 · Adagene Inc. ADAG · Company news
Pipeline & R&D
MAIA reports 88% disease control for ateganosine-cemiplimab in third-line NSCLC
17 Nov 2026 · MAIA Biotechnology, Inc. MAIA · Company news